BridgeMD
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
EU CTIS ID: 2022-502040-13-00
What this study is testing
Best CR/CRi/CRh during induction chemotherapy
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- AML or MDS-IB-2 according to WHO 2022 criteria
- “Intermediate or adverse risk” ELN 2022 category (for both MDS or AML)
- Intention to undergo intensive chemotherapy (CPX-351 or “7+3”) followed by allogeneic HSCT
You likely can't join if
- Not eligible for intensive chemotherapy
- Any prior treatment for AML or high-risk MDS (including magrolimab) except hydoxyurea
- Harboring a FLT3mut, regardless of FLT3-ITD or FLT3-TKD mutation status
- Acute promyelocytic leukemia (APL)
- Inadequate cardiac, pulmonary, renal, hepatic function
- ECOG ≥3
See the full eligibility criteria
- AML or MDS-IB-2 according to WHO 2022 criteria
- “Intermediate or adverse risk” ELN 2022 category (for both MDS or AML)
- Intention to undergo intensive chemotherapy (CPX-351 or “7+3”) followed by allogeneic HSCT
- Not eligible for intensive chemotherapy
- Any prior treatment for AML or high-risk MDS (including magrolimab) except hydoxyurea
- Harboring a FLT3mut, regardless of FLT3-ITD or FLT3-TKD mutation status
- Acute promyelocytic leukemia (APL)
- Inadequate cardiac, pulmonary, renal, hepatic function
- ECOG ≥3
- Active and uncontrolled infection
- Diagnosed or treated for another malignancy within 1 year before registration
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.